RayKnowChina Research Map
Shortlist0

RecruitingHepatocellular carcinomaN/A

Registered title, quoted from ClinicalTrials.gov

Microwave Ablation Simultaneously Combined With Lenavatinib for Recurrent Hepatocellular Carcinoma

An open trial on hepatocellular carcinoma, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 1 hospital on this site is listed as study site.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Study siteHunan Provincial People's Hospital湖南省人民医院(湖南师范大学附属第一医院)ChangshaHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT05444478, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 4

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (4 points)Hide the checklist
  1. 18 years to 75 years; sex: all

    Registered eligibility fields

  2. Primary HCC (BCLC 0-B), and the pathological results is hepatocellular carcinoma;

    Inclusion criterion 1

  3. Child-Pugh A or B(score of the B level is no more than 7)

    Inclusion criterion 7

  4. Baseline laboratory examinations meet the Criteria: Leukocyte ≥3.0×109/L; Blood platelet ≥75×109/L; Hemoglobin ≥100g/L; ALT、AST ≤ 3 x limit of normal(ULN); Serum creatinine ≤ 1.5 x ULN; Prothrombin time < ULN+4 s;INR < 1.5, Albumin ≥30g/L ; Total bilirubin ≤34mmol/L;

    Inclusion criterion 8

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: earlier treatment; day-to-day activity level; scans and measurable lesions; other conditions the trial excludes; pregnancy, breastfeeding and contraception.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT05444478, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Primary HCC (BCLC 0-B), and the pathological results is hepatocellular carcinoma;
  • recurrent HCC without any tumor related therapy;
  • Tumor number ≤3;
  • Tumor size ≤5cm;
  • Good performance, KPS≥90;
  • Age:18-75
  • Child-Pugh A or B(score of the B level is no more than 7)
  • Baseline laboratory examinations meet the Criteria: Leukocyte ≥3.0×109/L; Blood platelet ≥75×109/L; Hemoglobin ≥100g/L; ALT、AST ≤ 3 x limit of normal(ULN); Serum creatinine ≤ 1.5 x ULN; Prothrombin time < ULN+4 s;INR < 1.5, Albumin ≥30g/L ; Total bilirubin ≤34mmol/L;

Exclusion Criteria:

  • disagreeing to receive follow-up observation and participate the clinical study;
  • Accompanying with a history of other malignancies;
  • Accompanying with macrovascular invasion such as portal vain tumor thrombus, hepatic vein tumor thrombus;
  • with extrahepatic metastasis or lymph metastasis;
  • receiving system therapy such as targeted therapy or immunotherapy;
  • receiving local therapy such as ablation or TACE;
  • Any of the following occurred within 12 months of the study: myocardial infarction, severe / unstable angina, coronary artery bypass grafting, congestive heart failure, cerebrovascular accident (including transient ischemic attack), pulmonary embolism; ongoing arrhythmia by NCI-CTCA standard ≥ 2, prolonged QTc interval (450 ms for males, and> 470 ms for females;
  • other serious acute, chronic physiological or mental disorders or abnormal laboratory examination may increase the risk of participation in study treatment or may interfere with the interpretation of study findings or whom the investigator considers not fit;

Quoted from ClinicalTrials.gov, NCT05444478, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT05444478, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT05444478